Corporate Profile
To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Nov 04, 2022
Nov 04, 2022
Events
Jun 8, 2022 at 3:30 PM EDT
Jan 12, 2022 at 5:15 PM EST